Intralipid has recently become a widely accepted treatment for intravenous local anaesthetic toxicity. There is some reasonable animal evidence and a clear rationale for this indication, although controlled human studies have not been conducted to quantify the extent to which this translates into clinical benefits. However, over the last decade many enthusiasts have uncritically extrapolated the use of intralipid to oral overdose of several unrelated drugs, reporting a favourable outcome in unstructured case reports (containing limited detail) as if these provided evidence of effectiveness. These reports may provide 'food for thought' but are at best lowlevel evidence and their use to justify wider adoption of such treatments is clearly poor science. Worse, it may also be poor medicine and put patients' lives at risk in some situations.
The suggested use of intralipid in tricyclic antidepressant (TCA) overdose 1 provides a good example to illustrate these concerns. This relates to interpretation of case reports given the natural history, the expected effect of intralipid on bioavailability, clearance and distribution of TCAs, and the (lack of) evidence that should logically have preceded any use in patients for this indication.
THe naTural HisTory of TCa ingesTion
Claims of effectiveness of postulated new treatments in case reports often reflect a lack of experience in dealing with severe poisoning. The days of reporting a case report claiming a benefit because a patient survived and without supporting 'causal evidence' (discussed further in this paper) as to how benefits had occurred should be over. Intralipid should be no exception to this rule, but case reports flourish, claiming benefit for the treatment of poisonings that would have generally been expected to recover. These recent TCA cases involve the infusion of intralipid, often over a period of hours, when recovery would usually have been expected. Many other treatments are also being given over this long time frame, and concentrations of TCa fall rapidly over the first day due to redistribution (partly into the patient's own, much more plentiful, lipids).
TCA poisoning predominantly causes death out of hospital. for example, in a large single-centre series of consecutive TCA poisonings, the overall mortality was only 0.3% (one out of 302 patients). This cohort included many patients with heavy sedation, seizures and ventricular arrhythmias, and yet all but one recovered with mild alkalinisation, activated charcoal (selective patients) and good supportive care 2 .
THe expeCTed effeCT of inTralipid on THe pHarmaCokineTiCs of oral adminisTered drugs
The potential use of intralipid as an antidote for TCa overdose was first conceived, investigated and dismissed over 25 years ago 3 . Infusing half a kilogram of fat into a 70 kg person does not add appreciably to the lipid into which the drug can sequester, the concept of the creation of a 'lipid sink' into which a large amount of the drug will sequester is flawed; there is already a very large extravascular sink for lipid soluble drugs. for lipid soluble drugs the expected effect is a lipid vehicle, similar to adding a great deal of extra plasma protein binding sites. There has been extensive modelling of such effects, backed by experimental evidence. The most predictable effect is greatly altered distribution between the intravascular and extravascular compartments. on this basis, one can largely dismiss any research that involved measuring effects in isolated blood samples or organ preparations as irrelevant. under steady state conditions (input equals output and after reequilibration), the expected effect is for free drug concentrations in both tissue and plasma to be minimally altered, and this is precisely what has been demonstrated for amitriptyline and nortriptyline (figure 1) 3 .
Two further factors come into play in an oral overdose setting when there is ongoing (sometimes prolonged) absorption and distribution. Intralipid may temporarily increase the rate of absorption and reduce first-pass hepatic elimination (by temporarily lowering free serum concentrations) 4 . There is also a potential for intralipid to increase the rate of redistribution from well perfused tissues (e.g. heart and brain) to less well perfused tissues, resulting in both favourable and unfavourable kinetic effects from use of intralipid. It is thus concerning that people are being given this treatment for oral overdose when there have been no animal models demonstrating favourable effects under these circumstances 5 . The first oral poisoning animal model examining this issue demonstrated no effectiveness when intralipid was given during the absorption phase of parathion, and that it appeared to delay (but not prevent) toxicity when given later 6 . of even more concern, a recent animal study of oral amitriptyline overdose demonstrated increased bioavailability and enhanced toxicity when intralipid was given during the absorption phase 7 . All animal studies showing effectiveness against drug overdose have used animals poisoned via the intravenous route 5 .
The likely explanation for the dramatic difference in effectiveness seen between intravenous and oral animal models can be found in pharmacokinetic theory developed for protein binding interactions 8 . This predicts that intralipid would increase the elimination of high (but not low) extraction drugs given intravenously. This effect would not be predicted to decrease concentrations of orally administered drugs, as this would be offset by the increase in bioavailability 4, 8 . a flow chart for calculating when such binding reactions have favourable kinetic consequences with respect to free drug concentrations is shown (figure 2-adapted from an algorithm developed by rolan for protein binding interactions) 8 . It can also be predicted that if absorption is complete, but that distribution is ongoing, then a beneficial effect might also be seen (as this would be similar to the situation following an intravenous dose). However, one can only speculate how a clinician could conclude that such a situation existed, or even whether such a situation ever occurs in patients with life-threatening cardiac toxicity. The onset of most cardiac toxicity occurs early in the course of poisoning 9 or if delayed this is from drugs with extended release preparations 10 -in either situation, absorption is likely to be ongoing at the time of peak toxicity. Activated charcoal prior to use might help mitigate this risk in some circumstances. In conclusion, pharmacokinetic theory supports a likely benefit for intravenous drug cardiotoxicity and in cardiac arrest (counting on a very short-term reduction being useful) but not under other circumstances (figure 2).
evidenCe THaT sHould Have preCeded use in paTienTs wiTH oral overdose
By comparison with many other areas of medicine, the 'evidence base' to support poisoning treatments is sparse and of generally poor quality. This is a reflection of this being both a difficult area to research and an extremely neglected health priority with very little funded research. even with limited resources, it is both possible and vital to do research on animal models that resemble human poisoning 7 .
There is a model for successful development of new treatments established by industry. While industry support for new antidotes is minimal, independent researchers should aim to do studies that follow the same logical process of development-with appropriate animal models to establish dose/duration based on safety and likely efficacy, and then human volunteer studies to confirm these predictions.
The first trials involving patients should take the data from volunteer studies to select appropriate pharmacokinetic and biomarker outcomes and determine the timing of measurements that would provide causal evidence 11 : that is scientific evidence of the expected disease modifying action in the population. It is not necessary to randomise patients to have careful evaluation of dose/concentration/ time-response data. Conversely, simply randomising treatment of patients provides almost no useful information if patients are not carefully selected and such data are not collected 12, 13 . very small randomised studies with diverse patients and clinical outcomes can simply end up being a large collection of very poorly documented case reports.
ConClusion
intralipid seems likely to be of benefit in bupivacaine/lignocaine intravenous overdose, with the caveat that the optimal dose has never been established even in animals. There seems a potential role for it in established cardiac arrest by other highly lipid soluble drugs where cardiotoxicity is closely related to free plasma concentrations. Intralipid may interfere with other treatments used in the arrest (e.g. lignocaine), and bicarbonate is probably more useful in most situations as it is widely available and can be given rapidly to induce similar favourable effects on the distribution of these weak basic drugs. for other indications, clinicians would be wise to proceed with caution and recall previous fads in the treatment of poisoning based around simplistic logic that ended up being shown to have no effect (or increased mortality) and have now largely fallen by the wayside 14 
